Business Context and Reporting Period
This Form 8-K Current Report was filed by ChromaDex Corp. (not Niagen Bioscience, Inc.) on February 13, 2012, covering events occurring on February 7, 2012. The filing primarily addresses the appointment of Jeffrey Himmel as Chief Executive Officer and a member of the Board of Directors, along with the execution of his employment and indemnification agreements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It is a current report focused on corporate governance and executive compensation rather than financial performance.
Material Changes
The primary material change is the leadership transition and the establishment of a new executive compensation structure:
- Leadership Appointment: Jeffrey Himmel was appointed CEO and Director effective February 7, 2012, with his employment agreement retroactive to January 22, 2012.
- Compensation Structure: Mr. Himmel receives an annual base salary of $360,000, subject to a 5% annual increase and a one-time $50,000 increase upon the company listing on a major stock exchange.
- Equity Grants: The company granted 100,000 restricted shares, options to purchase 2,000,000 shares total, and an agreement to sell 1,000,000 restricted shares at $0.001 per share (subject to a stock price performance condition of $1.296).
- Bonus Plan: A target bonus of 100% of base salary is available for meeting budgeted revenue and EBITDA, with a maximum potential of 300%.
Guidance, Outlook, and Risks
The filing contains standard forward-looking statement disclaimers regarding uncertainties in securing capital and other risks. No specific financial guidance or outlook was provided in this document. The employment agreement includes significant severance provisions, including up to 12 months of base salary and accelerated vesting of equity in the event of termination without cause or a change of control.
Investor Verification Checklist
- Verify the company's current stock price relative to the $1.296 performance condition required for the vesting of 1,000,000 restricted shares.
- Confirm the company's current listing status to determine eligibility for the $50,000 salary increase.
- Review the full text of the Employment Agreement (Exhibit 10.1) for specific definitions of "Cause," "Good Reason," and "Change of Control."
- Assess the dilution impact of the 2,000,000 stock options and 1,100,000 restricted shares granted to the new CEO.
- Check subsequent filings for the company's ability to meet the budgeted revenue and EBITDA targets required for the CEO's bonus.